Nasdaq 100 2026 YTD Highs & Lows Radar: Electronic Arts, (EA), Lululemon Athletica inc (LULU) and more
MarketsFN Team
Nasdaq 100 2026 YTD Highs & Lows Radar: Electronic Arts, (EA), Lululemon Athletica inc (LULU) and more
Screening all 101 Nasdaq 100 constituents for stocks nearest to their 2026 year-to-date high and their 2026 YTD low. Data as of September 07, 2026. % Realized = total return since Jan 1 2026.
Legend: RSI > 70 = overbought · RSI < 30 = oversold · Green % Realized = positive YTD return · Red = negative.
📈 Nearest to 2026 High
Sectors represented: Healthcare (3), Communication Services (1), Technology (1)
| Ticker | Company | Sector | Price Last | % Realized | 2026 YTD High Date | RSI | % above MA200 | Trend |
|---|---|---|---|---|---|---|---|---|
| EA | Electronic Arts, Inc | Communication Services | $209.70 | +0.38% | 2026-08-04 | — | — | — |
| CDW | CDW Corp | Technology | $152.38 | +14.43% | 2026-08-04 | 60.6 | +15.6% | Above MA20, MA50, MA200 |
| AMGN | AMGEN Inc | Healthcare | $437.23 | +33.45% | 2026-09-03 | 61.9 | +22.0% | Above MA20, MA50, MA200 |
| BIIB | Biogen Inc | Healthcare | $220.83 | +24.19% | 2026-09-03 | 58.0 | +15.6% | Above MA20, MA50, MA200 |
| VRTX | Vertex Pharmaceuticals, Inc | Healthcare | $546.12 | +20.79% | 2026-09-03 | 59.4 | +17.2% | Above MA20, MA50, MA200 |
EA | Electronic Arts, Inc | Communication Services | Price Last: $209.70 | % Realized: +0.38% | RSI: — | % above MA200: — | Trend: —
Electronic Arts, Inc (EA) is a video game company that develops and publishes games such as FIFA and Madden NFL. Investors should care because its performance is tied to the gaming industry's growth and popularity of its flagship titles.
The stock is near its 2026 YTD high, up 0.4% YTD. Since MA data is incomplete and RSI(14) is N/A, we cannot assess momentum or MA alignment. The proximity to its YTD high may indicate a potential breakout.
CDW | CDW Corp | Technology | Price Last: $152.38 | % Realized: +14.43% | RSI: 60.6 | % above MA200: +15.6% | Trend: Above MA20, MA50, MA200
CDW Corp is a technology solutions provider offering a range of products and services to businesses, governments, and educational institutions. Investors should care because its diversified portfolio and strong customer relationships drive revenue growth.
CDW Corp's technicals indicate sustained uptrend with price > MA20 > MA50 > MA200, RSI(14) at 60.6, and 1.1% below its 2026 YTD high, suggesting momentum near a potential breakout level.
Related headlines
AMGN | AMGEN Inc | Healthcare | Price Last: $437.23 | % Realized: +33.45% | RSI: 61.9 | % above MA200: +22.0% | Trend: Above MA20, MA50, MA200
AMGEN Inc is a biotechnology company that develops and markets human therapeutics, focusing on innovative treatments for serious illnesses such as cancer, cardiovascular disease, and bone health conditions, making it an attractive investment for those seeking exposure to the biotech sector.
AMGN's technicals indicate sustained uptrend with price > MA20 > MA50 > MA200, RSI(14) at 61.9, and is 1.6% below its 2026 YTD high, suggesting momentum; the stock's proximity to its YTD high may signal a potential breakout.
Related headlines
BIIB | Biogen Inc | Healthcare | Price Last: $220.83 | % Realized: +24.19% | RSI: 58.0 | % above MA200: +15.6% | Trend: Above MA20, MA50, MA200
Biogen Inc is a biotechnology company that develops treatments for neurological diseases, such as multiple sclerosis and Alzheimer's. Investors should care because its therapies address significant unmet medical needs, potentially driving revenue growth.
Biogen's technicals indicate sustained uptrend with price ($220.83) above MA20 > MA50 > MA200. RSI(14) is 58.0, nearing overbought territory. The stock is 1.6% below its 2026 YTD high, suggesting potential breakout momentum.
Related headlines
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- Stoke Therapeutics and Biogen to present four-year zorevunersen data at epilepsy congress
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
- Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
VRTX | Vertex Pharmaceuticals, Inc | Healthcare | Price Last: $546.12 | % Realized: +20.79% | RSI: 59.4 | % above MA200: +17.2% | Trend: Above MA20, MA50, MA200
Vertex Pharmaceuticals, Inc is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious diseases. Investors should care because its cystic fibrosis treatments have shown significant market success and the company continues to expand its pipeline.
The stock is in a sustained uptrend with bullish MA alignment (price > MA20 > MA50 > MA200) and RSI(14) at 59.4, indicating momentum. It's 2.1% below its 2026 YTD high, near a potential breakout level, with 20.8% return over the 2026 YTD period.
Related headlines
- Vertex Completes $10 Billion Crinetics Acquisition, Adding Rare Endocrine Growth Platform
- Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
- Vertex to Participate in Upcoming September Investor Conferences
- Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails
📉 Nearest to 2026 Low
Sectors represented: Consumer Cyclical (1), Communication Services (1), Healthcare (1), Utilities (1), Consumer Defensive (1)
| Ticker | Company | Sector | Price Last | % Realized | 2026 YTD Low Date | RSI | % above MA200 | Trend |
|---|---|---|---|---|---|---|---|---|
| LULU | Lululemon Athletica inc | Consumer Cyclical | $100.61 | -52.27% | 2026-09-04 | 31.8 | -34.1% | Below MA20, MA50, MA200 |
| EA | Electronic Arts, Inc | Communication Services | $209.70 | +0.38% | 2026-07-17 | — | — | — |
| IDXX | Idexx Laboratories, Inc | Healthcare | $535.38 | -20.09% | 2026-06-30 | 41.4 | -11.8% | Below MA20, MA50, MA200 |
| EXC | Exelon Corp | Utilities | $43.64 | -0.64% | 2026-01-12 | 38.5 | -5.0% | Below MA20, MA50, MA200 |
| PEP | PepsiCo Inc | Consumer Defensive | $137.63 | -3.23% | 2026-07-23 | 42.0 | -7.5% | Below MA20, MA50, MA200 |
LULU | Lululemon Athletica inc | Consumer Cyclical | Price Last: $100.61 | % Realized: -52.27% | RSI: 31.8 | % above MA200: -34.1% | Trend: Below MA20, MA50, MA200
Lululemon Athletica inc is a premium athletic apparel retailer. Investors should care about its ability to maintain brand premiumization and navigate competitive pressures, directly impacting revenue growth and profitability.
Lululemon's technical situation is bearish, with RSI(14) at 31.8 indicating oversold conditions, and the stock below MA20, MA50, and MA200. It's testing major support at its 2026 YTD low, having fallen -52.3% YTD.
Related headlines
EA | Electronic Arts, Inc | Communication Services | Price Last: $209.70 | % Realized: +0.38% | RSI: — | % above MA200: — | Trend: —
Electronic Arts, Inc (EA) is a video game company that develops and publishes games such as FIFA and Madden NFL. Investors should care because its performance is tied to the gaming industry's growth and popularity of its flagship titles.
The stock is near its 2026 YTD high, up 0.4% YTD. Since MA data is incomplete and RSI(14) is N/A, we cannot assess momentum or MA alignment. The proximity to its YTD high may indicate a potential breakout.
IDXX | Idexx Laboratories, Inc | Healthcare | Price Last: $535.38 | % Realized: -20.09% | RSI: 41.4 | % above MA200: -11.8% | Trend: Below MA20, MA50, MA200
Idexx Laboratories, Inc is a veterinary diagnostics company providing testing solutions and software. Investors should care due to its significant market presence and growth potential in the animal healthcare sector.
IDXX is in a sustained downtrend with price < MA20 < MA50 < MA200, RSI(14) at 41.4, and is 1.7% above its 2026 YTD low, indicating a potential support test, which could be a warning sign for further downside.
Related headlines
- IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
- IDEXX Expands Catalyst Platform into Cardiac Disease with First and Only Dual-Species Point-of-Care NT-proBNP Test
- IDEXX Laboratories, Inc. Q2 2026 Earnings Call Summary
- IDEXX Laboratories Inc (IDXX) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and ...
EXC | Exelon Corp | Utilities | Price Last: $43.64 | % Realized: -0.64% | RSI: 38.5 | % above MA200: -5.0% | Trend: Below MA20, MA50, MA200
Exelon Corp is a utility company that generates and distributes electricity, operating nuclear, natural gas, and renewable energy facilities. Investors should care about its stable cash flows and regulatory environment, which impact its dividend sustainability and long-term growth prospects.
Exelon Corp's technical situation indicates a sustained downtrend with price ($43.64) below MA20, MA50, and MA200. The RSI(14) is 38.5, nearing oversold territory. The stock is 1.7% above its 2026 YTD low, testing major support, with a -0.6% 2026 YTD return, signaling potential further downside.
Related headlines
- Exelon Announces Key Leadership Position Changes
- Exelon Secures More Than $1 Billion in Customer Protections Through Pioneering Transmission Security Agreements
- Exelon high probability data center load falls 40%
- Exelon Corp (EXC) (Q2 2026) Earnings Call Highlights: Navigating Regulatory Hurdles and Data ...
PEP | PepsiCo Inc | Consumer Defensive | Price Last: $137.63 | % Realized: -3.23% | RSI: 42.0 | % above MA200: -7.5% | Trend: Below MA20, MA50, MA200
PepsiCo Inc is a global food and beverage leader with brands like Pepsi, Lay's, and Gatorade, generating revenue through diverse consumer products; investors care about its stable cash flows and dividend yield amidst changing consumer preferences.
PepsiCo's technicals indicate a warning sign with an RSI(14) of 42.0, below MA20/MA50/MA200, and a 2026 YTD return of -3.2%, sitting 2.0% above its YTD low, suggesting major support is being tested.
Related headlines
Market Commentary
The Nasdaq 100 stocks listed are near their 2026 year-to-date (YTD) extremes, with some close to their highs and others near their lows. Stocks like EA, CDW, AMGN, BIIB, and VRTX are within 2.1% of their 2026 YTD highs, while LULU, EA, IDXX, EXC, and PEP are near their YTD lows, with some having risen as little as 0.0% to 2.0% above their lows.
The technology sector and related stocks are influenced by various macro conditions and themes. The performance of these Nasdaq 100 stocks near their 2026 extremes may be driven by factors such as earnings reports, industry trends, and broader economic conditions. For instance, the biotechnology and pharmaceutical companies like AMGN, BIIB, and VRTX may be influenced by developments in their respective therapeutic areas and regulatory environments.
Investors and traders should monitor upcoming earnings announcements, industry developments, and macroeconomic indicators to gauge the future direction of these stocks. Specifically, they should watch how stocks like EA, which is near both its 2026 YTD high and low, react to new information, and whether the current trends near the extremes continue or reverse.
Methodology: All 101 Nasdaq 100 constituents screened. Close prices downloaded from 2026-01-01. Period high = highest close since Jan 1 2026; period low = lowest close since Jan 1 2026. Distance = (current price / period extreme − 1) × 100. Technical indicators computed on up to 1 year of daily OHLCV data.
Disclaimer: For informational purposes only. Not investment advice. Past performance is not indicative of future results.
